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Background: To compare oral misoprostol with 
intravenous oxytocin for labour augmentation in 
nulliparous women .  
Methods: Women(n=500) with regular contractions 
and an effaced cervix dilated between 3 and 9 cm, 
and who had inadequate uterine contractions (two or 
fewer contractions every 10 minutes) during the first 
stage of labour, were augmented with 75 μg oral 
misoprostol (single dose) or intravenous oxytocin. 
The primary parameters used to evaluate efficacy of 
misoprostol were the interval from the beginning of 
augmentation to vaginal delivery and the percentage 
of women who delivered their newborns vaginally 
within 6 to 12 hours of this interval. The primary 
parameters used to evaluate adverse events were 
incidence of tachysystole, hypertonus and uterine 
hyperstimulation. The secondary parameters used to 
evaluate efficacy or adverse events were rates of 
cesarean births, failure to progress and fetal 
distress.The neonatal outcomes included low Apgar 
score (less than 7 at 5 minutes after birth) and 
admission to the neonatal intensive care unit 
(NICU). Statistical significance was given to p< 0.05.  
Results: Of the 500 women, 250 were augmented 
with 75 μg oral misoprostol and 250 with titrated 
intravenous oxytocin.  
The mean interval from the beginning of 
augmentation to vaginal delivery was 6.53 hours in 
the misoprostol group, and 6.01 hours in the 
intravenous oxytocin group. Complete vaginal 
delivery occurred within 6 hours in 102 women 
(48.11%) in the misoprostol group and in 93 women 
(46.03%) in the oxytocin group (p value 0.647). There 
was no significant difference between the two 
groups who delivered vaginally within 12 hours. 
Side effects and neonatal outcomes also did not 
differ significantly between the two groups.  
Conclusion: Oral misoprostol may be an 
acceptable alternative to the traditional oxytocin for 
augmentation of labour. 
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Introduction 
      Prolonged labor is a common problem, especially 
among nulliparous women. Caesarean birth rates are 
greater than 20% in many developed countries. 1 The 
main diagnosis contributing to the high rate in 
nulliparous women is dystocia or prolonged labor. It 
can result in a negative birth experience  for the 
mother and can be associated with fetal distress 
resulting in emergency caesarean delivery. 2-4 
     The traditional standard way of augmentation of 
labour is intravenous oxytocin infusion which has to 
be titrated according to the severity and intensity of 
uterine contractions. Oxytocin is given by intravenous 
infusion and drip rate is calculated as number of drops 
per minute to adjust the dose in mIU / ml. It has to be 
regulated by I/V regulator and continuous monitoring 
is required. Inadvertent high dosage can result in 
uterine hyper stimulation, hypertonus, tachysystole 
and fetal distress while under dosage can result in 
prolonged labour and delayed delivery. 5 
     In view of increased patient's influx and lack of one 
to one care, regulation of intravenous infusion may be 
difficult. It can fluctuate due to movement of patient's 
hands or change of posture. Intravenous infusion may 
be associated with allergic reactions. I/V cannulation 
is also a painful procedure specially in women having 
thin veins. Oral misoprostol is a good alternative for 
labour augmentation especially in developing or low 
resource countries where infusion pumps are not 
available . It does not require continuous monitoring 
and I/V regulation.  
     Misoprostol, is a synthetic prostaglandin E1 
analogue It  was initially used to treat peptic ulcers 
caused by prostaglandin synthetase inhibitors. In April 
2002, the U.S. Food and Drug Administration revised 
the original labeling of misoprostol and approved it 
for use in pregnancy. 6 Misoprostol is used off-label for 
a variety of indications in the practice of obstetrics and 
gynecology, including medication abortion, medical 
management of miscarriage, induction of labor, 
cervical ripening before surgical procedures, and the 




treatment of postpartum hemorrhage.7 Misoprostol’s 
effects are dose dependent and include cervical 
softening and dilation, uterine contractions, nausea, 
vomiting, diarrhea, fever, and chills. Misoprostol’s 
advantages over other synthetic prostaglandin 
analogues are its low cost, long shelf life, lack of need 
for refrigeration, and worldwide availability. 7 
       Being a potent uterotropic and uterotonic agent, 
Misoprostol is a good alternative for labor 
augmentation.8 Based on misoprostol 
pharmacokinetics and clinical trial findings, including 
lower incidence of uterine hyperstimulation and a 
shorter active phase interval, oral misoprostol for labor 
induction can be given with consideration for 
individual differences and responses to its 
administration.9,10  
 
Patients and Methods 
This study was carried out from January 2012 – 
December 2012, in DHQ Teaching Hospital, 
Rawalpindi. Inclusion criteria were primigravidae, 
pregnancy between 37 and 42 weeks of gestation 
(n=500), a live singleton fetus in cephalic presentation, 
no history of uterine surgery, spontaneous onset of 
active labor with regular contractions, an effaced 
cervix dilated between 3 cm and 9 cm after rupture of 
membranes,clear liqour and a reassuring fetal heart 
rate (FHR) pattern. Exclusion criteria were non-
reassuring FHR pattern, multiparity, any 
contraindication to labor or vaginal delivery or both, 
significant maternal cardiac, renal, pulmonary or 
hepatic disease and hypersensitivity to misoprostol or 
prostaglandin analogues.  
     They were then divided into two groups .Group A 
(n=250) was augmented with single dose of 75 micro 
gram oral misoprostol, while Group B (n=250) was 
given titrated intravenous oxytocin infusion for 
augmentation of labour after artificial rupture of 
membranes.  In the titrated oxytocin group, oxytocin 
was given via intravenous route by infusion initially 
set to deliver 5 milliunit / min for 30 minutes, and 
then the dose increased by 5 milliunit / min every 30 
minutes by adjusting the number of drops in drip 
chamber until adequate uterine contractions were 
attained.  
      Adequate uterine contractions were defined as 
three moderate contractions (30 - 45 seconds)  ) in 10 
minutes. Tachysystole was defined as the presence of 
at least six contractions in 10 minutes for at least two 
10- minute windows. Hypertonus was defined as a 
single contraction lasting more than 2 minutes. 
Hyperstimulation was defined as tachysystole or 
hypertonus with non-reassuring FHR changes. FHR 
changes considered to be non-reassuring were late 
deceleration, severe variable deceleration, prolonged 
deceleration, tachycardia, or reduced FHR variability 
requiring intervention with either tocolytics or 
delivery. 
     The time of beginning of augmentation was noted 
down on partogram and the augmentation - delivery 
interval was calculated after delivery. The severity of 
uterine contractions was assessed by noting the 
duration of contractions by palpating maternal 
abdomen. The indications of caesarean section was 
also noted down. When tachysystole occurred, 
oxytocin was halted, and oxygen & hydration with 
lactated ringer's solution were given in both groups.  
Women who did not develop adequate uterine 
contractions with single dose of oral misoprostol were 
augmented with  intravenous oxytocin and were 
considered as failure of misoprostol. After delivery the 
APGAR score of the neonate was noted at 5 minutes in 
both groups. The number of neonates requiring NICU 
admission was noted in both groups 
     The primary parameters used to evaluate efficacy of 
misoprostol were the interval from the beginning of 
augmentation to vaginal delivery and the percentage 
of women who delivered their newborns vaginally 
within 6 to 12 hours of this interval. The primary 
parameters used to evaluate adverse events were 
incidence of tachysystole, hypertonus and uterine 
hyperstimulation. The secondary parameters used to 
evaluate efficacy or adverse events were rates of 
cesarean births, failure to progress and fetal 
distress.The neonatal outcomes included lower Apgar 
score (less than 7 at 5 minutes after birth) and 
admission to the neonatal intensive care unit (NICU).  
 
Results 
   The mean interval from the beginning of 
augmentation to vaginal delivery was 6.53 hours in 
Group ‘A’, and 6.01 hours, in Group ‘B’.  The failure 
rate of oral misoprostol was 11.0% (Table 1) i.e. 30 
patients who were given oral misoprostol did not 
develop adequate uterine contractions and required 
augmentation with IV oxytocin (Table 1). Of the 
women who completed vaginal delivery within 6 
hours, 48.11% were in Group ’A’ and 46.03% were in 
Group ‘B’ (p-value 0.647). There was also no 
significant difference between two groups who 
delivered vaginally within 12 hours (p-value 0.418). 
There was no significant difference in development of 
tachysystole, hypertonus or hyperstimulation between 
the two groups (Table 2). The fetal heart beat pattern 




returned to normal within 5 minutes in six of these 
women so they had vaginal deliveries while four 
women who developed hyperstimulation underwent 
emergency caesarean delivery for non-reassuring FHR. 
Two Hundred and Twelve patients (84.80%) in Group 
‘A’ had vaginal deliveries compared with 202 patients 
(80.80%) in Group ‘B’       (p-value 0.097). While 38 
patients (15.20%) underwent caesarean section in 
Group ‘A’ as compared to 48 patients (19.20%) in 
Group ‘B’ (p-value 0.097). The indications for 
caesarean delivery were failure of labor to progress 
and fetal distress (Table: 3).  
     There was no significant difference in neonatal 
outcomes between two groups.Seven newborns 
(2.80%) in Group ‘A’ had APGAR score <7 at 5 
minutes after delivery as compared to 10 neonates 
(4.0%) in Group ‘B’ (p-value 0.460). In oral misoprostol 
group, 25 babies (10.0%) were admitted in NICU as 
compared to 32 babies (12.80%) in intravenous 
oxytocin group (p-value 0.326) (Table 4).. 
 
Table 1:Success Rate (n=250 in each group) 






to delivery interval 
(hrs) 
6.53 6.01 0.000 
Vaginal delivery in 6 
hours 
102(48.11) 93(46.03) 0.647 
Vaginal delivery in 12 
hours 
110(51.88) 109(53.96) 0.000 
Failure Rate 30(11.00) -(-) 0.000 
p-value < 0.05  Significant ;p-value > 0.05  Not Significant  
 
Table 2- Effects of Uterine Contractility (n=250 in 
each group)  





Tachysystole 12(4.8) 20(8.00) 0.144 
Hypertonus 0(-) 0(-) - 
Hyperstimulation 4(1.60) 6(2.40) 0.524 
p-value < 0.05  Significant ;p-value > 0.05  Not Significant   
 
Table 3: Mode of Delivery (n=250 in each group) 





1.Vaginal 212(84.80) 202(80.80) 0.097 
2.C-Section 38(15.20) 48(19.20) 0.097 
(i)Failure to progress 12(31.57) 18(37.50 0.259 
       Fetal malposition 5(41.66) 6(33.330 - 
       Cephalopelvic   
         disproportion  
3(25.00) 7(38.88) - 
        Dysfunctional  
          labour 
4(33.33) 5(27.77) 0.257 
(ii) Fetal distress 26(68.42) 30(62.50) 0.257 
p-value < 0.05  Significant ;p-value > 0.05  Not Significant  
The common side effects of misoprostol included 
vomiting, diarrohea, pyrexia, and shivering. (Table: 5) 
Six women in both groups went into postpartum 
haemorrhage but it was managed with medical 
measures except for one patient in Group ‘A’ who 
required uterine and internal iliac arteries ligation 
Table 4: Neonatal Outcome 





5 minutes APGAR 
Score <7 
7(2.80) 10(4.00) 0.460 
Neontal ICU 
admission 
25(10.00) 32(12.60) 0.328 
p-Value < 0.05 Significant;p-Value > 0.05 Not Significant 
 
Table 5. Maternal outcome (n=250 in each group) 




Vomiting 3(1.20) -(-) 
Diarrhoea -(-) -(-) 
Shivering 5(2.00) 2(0.80) 
Pyrexia  3(1.20) -(-) 
Postpartum haemorrhage 6(2.40) 6(2.40) 
 
Discussion 
      Caesarean birth rates are greater than 20% in many 
developed countries.1 A policy of early amniotomy 
with oxytocin administration for the prevention of 
delay in labor progress is associated with a modest 
reduction in the rate of cesarean births.8 There is no 
significant difference in cesarean delivery rate, 
neonatal outcome, and maternal outcome between the 
low and high doses of oxytocin on labor augmentation 
except for labor augmentation interval. 11 Oxytocin 
administration through the intravenous route needs to 
be under the control of an intravenous pump machine 
and may be inconvenient for patients. But oral 
misoprostol is easier to administer than titrated 
intravenous oxytocin.Misoprostol offers several 
advantages over oxytocin such as longer shelf life, 
stability at room temperature, and easy 
administration. It avoids intravenous infusion and 
continuous monitoring. It also relieves patient's 
anxiety and allows easily mobility. It is an acceptable 
alternative to traditional oxytocin  for labour  
augmentation. 
     According to the pharmacokinetics, the onset time 
and administration route of oxytocin is better than that 
of misoprostol. In this study, it was expected that the 
titrated intravenous oxytocin would be more effective 
than oral misoprostol in terms of the interval of 
augmentation to vaginal delivery. However, the 
difference of these intervals is not significant in actual 




clinical practice. Vaginal delivery within 6 to 12 hours 
is the more important clinical factor. Present study 
found no significant difference between the two 
groups in the percentages of women who delivered 
their newborns vaginally within 6 to 12 hours of 
augmentation. Therefore, labor augmentation with 
oral misoprostol is an effective alternative method.An 
oral dose of 75 μg of misoprostol given at a 4-hour 
interval for a maximum of 2 doses is the highest 
tolerated dose.12  
     Women in the misoprostol group are more likely to 
experience uterine tachysystole and hypertonus 
compared with those in the oxytocin group. This 
increase is secondary to uterine hypertonus as the 
incidence of tachysystole did not differ between two 
groups. Women in the misoprostol arm were no more 
likely to experience a nonreassuring fetal heart rate or 
require a caesarean delivery for this indication. There 
were no significant differences in maternal or neonatal 
outcomes.13 Orally administered misoprostol 
compared with titrated intravenous oxytocin for labor 
induction in women with favorable cervical condition 
(Bishop score of 6 or more) showed higher likelihood 
of uterine hyperstimulation with oral misoprostol. 14 In 
our study, the rates of hyperstimulation and 
tachysystole were lower with oral misoprostol 
probably because we used single dose of 75 
microgram oral misoprostol and our study was limited 
to nulliparous women. There was also no significant 
difference between the two groups regarding neonatal 
outcomes and NICU admission in our study. 
 
Conclusion 
1. Oral misoprostol is observed to be similar to 
intravenous oxytocin infusion in labor 
augmentation and may be an alternative to the 
traditional oxytocin.  
2. Longer shelf life, stability at room temperature, 
and easy administration of misoprostol offers 
added advantages over oxytocin . 
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